These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 16934041

  • 1. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW, Lilitkarntakul P, Webb DJ.
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [Abstract] [Full Text] [Related]

  • 2. EU orphan regulation--ten years of application.
    Michaux G.
    Food Drug Law J; 2010 Sep; 65(4):639-69, i-ii. PubMed ID: 24479246
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 5. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 6. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr 05; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rare diseases and orphan drugs.
    Taruscio D, Capozzoli F, Frank C.
    Ann Ist Super Sanita; 2011 Apr 05; 47(1):83-93. PubMed ID: 21430345
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb 05; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 12. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M, Kubácková K, Palágyi M, Smíd M.
    Cas Lek Cesk; 2006 Feb 05; 145(4):296-300. PubMed ID: 16639930
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 15. [European incentives for orphan medicinal products].
    Enzmann H, Lütz J.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May 19; 51(5):500-8. PubMed ID: 18696141
    [Abstract] [Full Text] [Related]

  • 16. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R, Bertele' V, Garattini S.
    Eur J Clin Pharmacol; 2013 Apr 19; 69(4):1009-24. PubMed ID: 23090701
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S, Compagni A, Reich MR.
    Int J Health Plann Manage; 2009 Apr 19; 24(1):27-42. PubMed ID: 18435430
    [Abstract] [Full Text] [Related]

  • 19. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W, Denier Y, Dooms M, Cassiman JJ, Dierickx K.
    J Med Ethics; 2012 Mar 19; 38(3):148-53. PubMed ID: 21947805
    [Abstract] [Full Text] [Related]

  • 20. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May 19; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.